StreetInsider.com News Articles

Form 144 Ovid Therapeutics Inc. Filed by: Rona Jeffrey A

Fri, 14 Aug 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260814/26933134.html

Form 144 Ovid Therapeutics Inc. Filed by: Rona Jeffrey A

Fri, 14 Aug 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260814/26933134.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260814/26932618.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260814/26932618.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932169.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932169.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC

Fri, 14 Aug 2026 11:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26927346.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC

Fri, 14 Aug 2026 11:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26927346.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924137.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924137.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26921002.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26921002.html

Form 10-Q Ovid Therapeutics Inc. For: Jun 30

Thu, 13 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26917138.html

Form 10-Q Ovid Therapeutics Inc. For: Jun 30

Thu, 13 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26917138.html

Form 8-K Ovid Therapeutics Inc. For: Aug 11

Thu, 13 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26917130.html

Form 8-K Ovid Therapeutics Inc. For: Aug 11

Thu, 13 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26917130.html

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:30:00 -0400

First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 study
Initiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitor
A newly-formed portfolio company with funds advised by Perceptive Advisors acquired global rights to soticlestat; Ovid secured equity in the company and the potential to receive regulatory and sales milestone payments and royalties upon success
Strengthened executive leadership team with appointment of Kevin Norrett as Chief Business Officer and Eliseo Salinas, MD, as Executive R&D Advisor
Cash, cash equivalents and marketable securities were $169.8 million as of June 30, 2026; expected financial runway into 2029
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:30:00 -0400
- First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 study
- Initiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitor
- A newly-formed portfolio company with funds advised by Perceptive Advisors acquired global rights to soticlestat; Ovid secured equity in the company and the potential to receive regulatory and sales milestone payments and royalties upon success
- Strengthened executive leadership team with appointment of Kevin Norrett as Chief Business Officer and Eliseo Salinas, MD, as Executive R&D Advisor
- Cash, cash equivalents and marketable securities were $169.8 million as of June 30, 2026; expected financial runway into 2029
  
  Ovid Therapeutics Inc (OVID) PT Raised to $9 at Oppenheimer
  
  Mon, 03 Aug 2026 08:35:05 -0400
  Oppenheimer analyst Jay Olson raised the price target on Ovid Therapeutics Inc (NASDAQ: OVID) to $9.00 (from $7.00) while maintaining a Outperform rating.
  
  Form SCHEDULE 13G Ovid Therapeutics Inc. Filed by: BlackRock, Inc.
  
  Wed, 29 Jul 2026 15:23:00 -0400
  si-local-file:///var/storage/secattach/20260729/26834402.html
  
  Form SCHEDULE 13G Ovid Therapeutics Inc. Filed by: BlackRock, Inc.
  
  Wed, 29 Jul 2026 15:23:00 -0400
  si-local-file:///var/storage/secattach/20260729/26834402.html
  
  B.Riley on Ovid Therapeutics Inc (OVID): 'one of our top picks from last week's B. Riley MMV Summit'
  
  Tue, 21 Jul 2026 05:16:13 -0400
  
  B.Riley analyst Madison El-Saadi reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).
  The analyst comments "We reiterate our Buy rating and $5 PT on OVID, one of our top picks from last week's B. Riley MMV Summit (7/16 fireside and panel with CEO Meg Alexander), and continue to view the risk/ reward as compelling against a 39% YTD move vs XBI 27%. We see the dense stack of YE26- to-early-27 readouts across OV329 and KCC2 as sufficient to unlock the next leg of the story. The asymmetric re-rating drivers are, in our view: (1) OV329
  
  B.Riley on Ovid Therapeutics Inc (OVID): 'one of our top picks from last week's B. Riley MMV Summit'
  
  Tue, 21 Jul 2026 05:16:13 -0400
  
  B.Riley analyst Madison El-Saadi reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).
  The analyst comments "We reiterate our Buy rating and $5 PT on OVID, one of our top picks from last week's B. Riley MMV Summit (7/16 fireside and panel with CEO Meg Alexander), and continue to view the risk/ reward as compelling against a 39% YTD move vs XBI 27%. We see the dense stack of YE26- to-early-27 readouts across OV329 and KCC2 as sufficient to unlock the next leg of the story. The asymmetric re-rating drivers are, in our view: (1) OV329
  
  Form 4 Ovid Therapeutics Inc. For: Jul 06 Filed by: Carter Charles Ross
  
  Wed, 08 Jul 2026 16:32:00 -0400
  si-local-file:///var/storage/secattach/20260708/26747955.html
  
  Form 4 Ovid Therapeutics Inc. For: Jul 06 Filed by: Carter Charles Ross
  
  Wed, 08 Jul 2026 16:32:00 -0400
  si-local-file:///var/storage/secattach/20260708/26747955.html

StreetInsider.com News Articles

Form 144 Ovid Therapeutics Inc. Filed by: Rona Jeffrey A

Form 144 Ovid Therapeutics Inc. Filed by: Rona Jeffrey A

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: ADAR1 Capital Management, LLC

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: ADAR1 Capital Management, LLC

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: Affinity Asset Advisors, LLC

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: Affinity Asset Advisors, LLC

Form 10-Q Ovid Therapeutics Inc. For: Jun 30

Form 10-Q Ovid Therapeutics Inc. For: Jun 30

Form 8-K Ovid Therapeutics Inc. For: Aug 11

Form 8-K Ovid Therapeutics Inc. For: Aug 11

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Ovid Therapeutics Inc (OVID) PT Raised to $9 at Oppenheimer

Form SCHEDULE 13G Ovid Therapeutics Inc. Filed by: BlackRock, Inc.

Form SCHEDULE 13G Ovid Therapeutics Inc. Filed by: BlackRock, Inc.

B.Riley on Ovid Therapeutics Inc (OVID): 'one of our top picks from last week's B. Riley MMV Summit'

B.Riley on Ovid Therapeutics Inc (OVID): 'one of our top picks from last week's B. Riley MMV Summit'

Form 4 Ovid Therapeutics Inc. For: Jul 06 Filed by: Carter Charles Ross

Form 4 Ovid Therapeutics Inc. For: Jul 06 Filed by: Carter Charles Ross